Table 5 Hematologic and non-hematologic treatment-emergent adverse events.
TEAE | Total (N = 248) | |
|---|---|---|
Any grade, n (%)a | Grade 3/4, n (%)a | |
Hematologic TEAEsb | ||
Total patients with hematologic TEAE | 106 (42.7) | 85 (34.3) |
Anemia | 64 (25.8) | 27 (10.9) |
Thrombocytopenia | 57 (23.0) | 44 (17.7) |
Neutropenia | 39 (15.7) | 33 (13.3) |
Leukopenia | 18 (7.3) | 12 (4.8) |
Lymphopenia | 16 (6.5) | 14 (5.6) |
Non-hematologic TEAEsb | ||
Infections and infestations | 71 (28.6) | 16 (6.5) |
Nervous system disorders | 49 (19.8) | 8 (3.2) |
General disorders and administration site conditions | ||
Pyrexia | 31 (12.5) | 6 (2.4) |
Fatigue | 30 (12.1) | 2 (0.8) |
Asthenia | 23 (9.3) | 2 (1.2) |
Peripheral edema | 19 (7.7) | 1 (0.4) |
Gastrointestinal disorders | ||
Diarrhea | 38 (15.3) | 2 (0.8) |
Nausea | 23 (9.3) | 3 (1.2) |
Constipation | 14 (5.6) | 0 |
Vomiting | 14 (5.6) | 2 (0.8) |
Metabolism and nutrition disorders | 31 (12.5) | 9 (3.6) |
Musculoskeletal and connective tissue disorders | ||
Back pain | 20 (8.1) | 4 (1.6) |
Arthralgia | 15 (6.0) | 3 (1.2) |
Respiratory, thoracic, and mediastinal disorders | ||
Dyspnea | 28 (11.3) | 6 (2.4) |
Investigations | 25 (10.1) | 6 (2.4) |
Psychiatric disorders | 22 (8.9) | 3 (1.2) |
Renal and urinary disorders | 22 (8.9) | 13 (5.2) |
Injury, poisoning and procedural complications | 21 (8.5) | 6 (2.4) |
Skin and subcutaneous tissue disorders | 20 (8.1) | 1 (0.4) |
Cardiac disorders | 18 (7.3) | 9 (3.6) |
Vascular disorders | 18 (7.3) | 7 (2.8) |
